See more : Ricoh Company, Ltd. (RICOY) Income Statement Analysis – Financial Results
Complete financial analysis of Aditxt, Inc. (ADTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aditxt, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Mudrick Capital Acquisition Corporation II (MUDS) Income Statement Analysis – Financial Results
- PTT Public Company Limited (PETFF) Income Statement Analysis – Financial Results
- MonotaRO Co., Ltd. (3064.T) Income Statement Analysis – Financial Results
- American Business Corp. (ARBU) Income Statement Analysis – Financial Results
- Shibuya Corporation (6340.T) Income Statement Analysis – Financial Results
Aditxt, Inc. (ADTX)
About Aditxt, Inc.
Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 645.18K | 933.72K | 105.03K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 756.84K | 766.78K | 77.98K | 17.77K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -111.66K | 166.94K | 27.06K | -17.77K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | -17.31% | 17.88% | 25.76% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 7.07M | 7.27M | 5.04M | 937.97K | 175.44K | 525.00K | 0.00 |
| General & Administrative | 18.61M | 15.99M | 22.08M | 7.85M | 5.69M | 5.04M | 851.94K |
| Selling & Marketing | 269.28K | 1.85M | 334.98K | 81.99K | 551.00 | 39.84K | -638.96K |
| SG&A | 18.88M | 17.84M | 22.42M | 7.93M | 5.70M | 5.08M | 212.99K |
| Other Expenses | 0.00 | 58.96K | 14.42M | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 25.95M | 25.10M | 27.46M | 8.87M | 5.87M | 5.61M | 212.99K |
| Cost & Expenses | 26.71M | 25.87M | 27.54M | 8.87M | 5.87M | 5.61M | 212.99K |
| Interest Income | 10.17K | 57.35K | 3.10K | 563.00 | 1.93K | 0.00 | 0.00 |
| Interest Expense | 6.39M | 2.29M | 1.94M | 310.08K | 1.93K | 79.77K | 0.00 |
| Depreciation & Amortization | 542.58K | 535.98K | 476.24K | 17.77K | 5.87M | 5.61M | 851.94K |
| EBITDA | -25.46M | -24.83M | -43.96M | -8.85M | 45.00K | 0.00 | 638.96K |
| EBITDA Ratio | -3,945.89% | -2,600.78% | -25,663.68% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -26.06M | -24.94M | -27.43M | -8.87M | -5.87M | -5.61M | -212.99K |
| Operating Income Ratio | -4,039.58% | -2,670.64% | -26,120.04% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -6.33M | -2.17M | -4.44M | -277.02K | 43.07K | -79.77K | 0.00 |
| Income Before Tax | -32.39M | -27.65M | -46.37M | -9.15M | -5.83M | -5.69M | -212.99K |
| Income Before Tax Ratio | -5,020.40% | -2,961.28% | -44,148.91% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 543.94K | 1.94M | 310.08K | 1.93K | -161.14K | -851.94K |
| Net Income | -32.38M | -28.19M | -48.31M | -9.46M | -5.83M | -5.69M | -212.99K |
| Net Income Ratio | -5,018.92% | -3,019.53% | -45,994.56% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -108.15 | -608.04 | -5.06K | -1.46K | -2.25K | -2.90K | -82.35 |
| EPS Diluted | -108.15 | -608.04 | -5.06K | -1.46K | -2.25K | -2.90K | -82.35 |
| Weighted Avg Shares Out | 302.36K | 46.37K | 9.55K | 6.49K | 2.59K | 1.96K | 2.59K |
| Weighted Avg Shares Out (Dil) | 302.36K | 46.37K | 9.55K | 6.49K | 2.59K | 1.96K | 2.59K |
Aditxt, Inc. Regains Compliance with Nasdaq Stockholders' Equity Requirement
RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt” or “the Company”) (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, today announced that it has received confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) Hearing Panel that it has...
Aditxt shares sink on pricing of $6M private placement
Aditxt Inc's shares fell more than 20% in Tuesday premarket trading after the company announced the pricing of a $6 million private placement of shares and accompanying warrants. The Richmond, Virginia-based medical technologies company said it entered definitive agreements for...
Aditxt Announces $6 Million Private Placement Priced At-The-Market under Nasdaq Rules
RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc., (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced that it has entered into definitive agreements for the purchase and...
EVOFEM BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Evofem Biosciences, Inc. - EVFM
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Evofem Biosciences, Inc. (OTC: EVFM) to Aditxt, Inc. (NasdaqCM: ADTX) in...
Why Is Aditxt (ADTX) Stock Up 58% Today?
Aditxt (NASDAQ: ADTX ) stock is rallying higher on Tuesday after the biotech company announced its plan to acquire Evofem Biosciences (OTCMKTS: EVFM ). According to a press release, Aditxt has agreed to acquire Evofem Biosciences in a deal worth...
Aditxt (ADTX) stock price just soared but gains could be brief
The Aditxt (NASDAQ: ADTX) stock price jumped by more than 83% on Tuesday, making it one of the best performers in Wall Street. The shares surged to a high of $9.47, its highest point since October 19th.
ADTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Aditxt, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Aditxt, Inc. (NASDAQ: ADTX) and Evofem Biosciences, Inc. is fair to Aditxt shareholders. Halper Sadeh encourages Aditxt shareholders to click here to learn more...
Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc., Creator of Phexxi®, the First and Only FDA-Approved Hormone-Free Contraceptive Gel, to Address Diverse Reproductive Health Needs of Women Globally
RICHMOND, Va. & SAN DIEGO--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, and Evofem Biosciences, Inc. (“Evofem”) (OTCQB: EVFM), a pioneer in women's health, today announced the signing...
Why Is Aditxt (ADTX) Stock Up 70% Today?
Aditxt (NASDAQ: ADTX ) stock is rocketing higher on Thursday despite a lack of news from the biotechnology company. There are no new press releases or filings with the Securities and Exchange Commission (SEC) that explain why ADTX stock is up...
Aditxt, Inc. to Present at 8th Annual Dawson James Conference
Chief Executive Officer, Amro Albanna to Present at 9:00am Eastern Time on Thursday, October 12, 2023 Chief Executive Officer, Amro Albanna to Present at 9:00am Eastern Time on Thursday, October 12, 2023
Source: https://incomestatements.info
Category: Stock Reports